|
⚲
|
| Keyboard |
| Logos Global Management LP
✚
|
|
|---|---|
| CRD # | 305162 |
| SEC # | 801-117248 |
| CIK # | 0001792126 |
| AUM | 2,252.5 M (2026-04-22) |
| Employees | 9 (56% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 415-801-4660 |
| Address | 1 Letterman Drive San Francisco, CA 94129 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Investors should consult the Offering Documents for more details regarding the calculation of fees and expenses. Fees and Allocations The Investors and the Funds are qualified purchasers. Therefore, information on how Logos is compensated for its advisory services and its fee schedule are not included here. Logos’ compensation is negotiable and varies, but is set forth generally in each Fund’s Offering Document. The General Partners serve as the general partners of each Fund that is a limited partnership. As such, the General Partners deduct management fees and performance allocations directly from the applicable Funds or are distributed carried interest distributions, as applicable. Investors in a feeder fund pay fees and allocations indirectly, through their indirect investments in the Master Fund. Management fees are deducted in advance on the first day of each fiscal quarter, performance allocations are allocated at the end of each fiscal year or at the time of an investor’s withdrawal or redemption and carried interest distributions are generally made on distributions from the applicable Funds following the return of capital to Investors. If a Fund terminates or an Investor withdraws or redeems, the Investor (through the Master Fund) bears expenses, management fees and performance allocations through the date of termination or withdrawal/redemption, except that if an Investor withdraws or redeems from a Fund on a date other than the last day of a measurement period, there is no refund to that Investor of any management fee that it previously paid for that period. Investors may not withdraw from the Opportunities Funds or any special purpose vehicles. Logos and its personnel may receive additional compensation in connection with management and other services performed for portfolio companies of the Funds and such additional compensation offsets, in part, the management fees otherwise payable to Logos to the extent provided in the Offering Documents. Logos provides certain Investors special management fee, performance allocation and carried interest arrangements that it does not provide to other Investors. Logos may waive all or any portion of the management fees, performance allocations and carried interest distributions with respect to any Investor. The Offering Documents of certain Opportunities Funds or special purpose vehicles permit Logos to waive or agree to reduce its management fee, which reductions operate to reduce the amount of capital Logos, the applicable General Partner or certain affiliated persons would otherwise be required to contribute to that Opportunities Fund. As described in the Offering Documents, the Limited Partners of such an Opportunities Fund are, in such circumstances, required to make special contributions according to their respective share of the management fee to fund any contribution corresponding to the waived or reduced management fee. As a result, the exercise of such waiver may result in an acceleration (or delay) of investor capital contributions and depending on the timing of waivers and contributions, it is possible that management fee reductions or waivers will not be fully realized by investors in an Opportunities Fund, resulting in a benefit to Logos. Performance allocations and carried interest distributions may create an incentive for Logos to make more risky and speculative investments than it would otherwise make. Logos believes that its fees are competitive with fees charged by other investment advisers for comparable services. Comparable services may be available, however, from other sources for lower fees. Expenses In addition to the compensation described above, each Fund bears the costs and expenses of its formation and operation as more fully disclosed in the Offering Documents. Investors should review the applicable Fund’s Offering Documents for a more detailed description of that Fund’s expenses. These expenses include, but are not limited to the following: (1) trading and investment expenses, including, as applicable, research fees and expenses; (2) legal and compliance expenses; (3) fees and expenses related to various filings (or portions thereof) made in connection with managing the Funds’ portfolios (including, but not limited to, Section 13 filings, Form PF preparation and filings and similar expenses (if applicable)); (4) administrator, audit (including custody audit, if applicable), tax and Fund- related accounting expenses (including third party accounting services); (5) shareholder proxy voting services; (6) organizational expenses; (7) interest on margin accounts and other indebtedness; (8) borrowing charges on securities sold short; (9) custodial and bank service fees; (10) third party valuation services; (11) expenses and costs of expert networks and costs of obtaining surveys; (12) software, data sets and analysis or other information related to investments or sectors in which the Funds may invest; (13) Fund-related insurance costs; (14) litigation or investigation expenses involving Fund activities; and (15) any other expenses related to the purchase, sale or transmittal of the Funds’ assets. Transaction-Based Compensation From time to time and in connection with the Funds’ portfolio investments, Logos, its affiliates or its supervised persons may receive transaction, commitment, breakup, advisory, syndication, guarantee, directors, officers, management and other fees. Such fees received by Logos are generally offset in whole or part against management or other fees payable to Logos by the relevant Fund(s). However, in certain instances Logos, its affiliates or supervised persons will retain a portion of such fees without a corresponding fee offset. Please refer to the governing documents of the applicable Fund for complete information on additional compensation received by Logos in connection with services ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients Logos provides investment advisory services to the Funds. Investors in the Funds will include but will not be limited to high-net-worth individuals, trusts, estates, charitable organizations, endowments, foundations, insurance companies, funds of funds, family offices, public and corporate pension plans and other corporate and business entities. Investors in the Public Funds are required to make an initial minimum subscription of $5 million, subject to waiver by Logos. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 0.2 | ||
| Erasca Inc | 0.2 | ||
| IDEAYA Biosciences Inc | 0.1 | ||
| Praxis Precision Medicines Inc | 0.1 | ||
| Abivax Sa | 0.1 | ||
| BCTG Acquisition Corp | 0.1 | ||
| Cytokinetics Inc | 0.1 | ||
| Olema Pharmaceuticals Inc | 0.0 | ||
| United Therapeutics Corp | 0.0 | ||
| Immunocore Holdings PLC | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Logos Opportunities Fund V LP | [2026-03-31] | 250.2 M | |
| Filed 2025-02-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Logos Opportunities Fund IV LP | [2024-03-29] | 284.0 M | 361.9 M |
| Filed 2024-07-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Logos Opportunities Fund III LP | [2022-03-31] | 208.1 M | 68.0 M |
| Filed 2021-05-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Logos SPV 1 LP | [2022-03-31] | ||
| Filed 2021-01-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Logos Opportunities Fund II LP | [2021-03-31] | 44.0 M | 42.1 M |
| Filed 2020-02-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Logos Opportunities Fund I LP | [2019-12-23] | 44.0 M | |
| Filed 2020-02-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Logos Global Master Fund LP | [2019-07-26] | 266.1 M | 1,530.3 M |
| Filed 2025-08-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 2.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 2.3 |
| By Discretionary | ||
| Discretionary | 8 | 2.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 2.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.8 | |
| United States Persons | 1.5 | |
| Total | 8 | 2.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Ronan Guilfoyle | Director | 358 | 108 | |
| Wade Kenny | Director | 86 | 31 | |
| Virginia Yee | Executive Officer | 7 | 3 | |
| Arsani William | Director, Executive Officer | 9 | 2 | |
| Graham Walmsley | Executive Officer | 9 | 2 | |
| Edward Zhong | Executive Officer | 6 | 2 | |
| Yanni Souroutzidis | Executive Officer | 4 | 2 | |
| Edward Callaway | Executive Officer | 4 | 2 | |
| Derek Gould | Executive Officer | 3 | 2 | |
| Logos GP LLC | Executive Officer | 3 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001792126] | |
| 3 | [0001792126] | |
| 4 | [0001792126] | |
| SC 13D | [0001792126] | |
| SC 13G | [0001792126] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 5493000DTXD20QIYQ102 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Verve Therapeutics Inc | |
| Logos Global Management LP | |
| Tokai Pharmaceuticals Inc | |
| Dyne Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Buy | 370,000 | $19.00 | 7,030,000 |
|
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
|
2021-06-21 | Conversion | 4,104,416 | ||
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Conversion | 443,265 | ||
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Sell | 12,942 | $26.64 | 344,775 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 12,942 | $25.88 | 334,939 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Sell | 27 | $27.02 | 730 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 15,000 | $26.17 | 392,550 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 5,000 | $24.03 | 120,150 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 31,000 | $24.53 | 760,430 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 4,000 | $25.97 | 103,880 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 15,000 | $26.48 | 397,200 |
|
Tokai Pharmaceuticals Inc NVUS
Common Stock
|
2020-10-30 | Buy | 9,098 | $25.55 | 232,454 |
|
Dyne Therapeutics Inc DYN
Series B Preferred Stock · derivative
|
2020-09-21 | Conversion | 2,668,089 | $0.00 | |
|
Dyne Therapeutics Inc DYN
Common Stock
|
2020-09-21 | Conversion | 804,392 | ||
|
Dyne Therapeutics Inc DYN
Common Stock
|
2020-09-21 | Buy | 700,000 | $19.00 | 13,300,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Jana Partners Management LP
✚
|
NY | 2,286.4 M |
|
Clocktower Group LP
✚
|
CA | 2,283.0 M |
|
Asset Value Investors Limited
✚
|
2,280.8 M | |
|
M Square Investimentos LTDA
✚
|
2,251.5 M | |
|
Browning West LP
✚
|
CA | 2,243.7 M |
|
Troluce Capital Advisors LLC
✚
|
PR | 2,242.4 M |
|
Entropy Technologies LP
✚
|
NY | 2,238.1 M |
|
Passaic Partners LLC
✚
|
NJ | 2,237.5 M |
|
Absolute Investment Advisers LLC
✚
|
FL | 2,233.9 M |
|
APS Asset Management PTE Ltd
✚
|
2,225.9 M |